Follow The Filings

LH Labcorp

Health Care, filed as LABCORP HOLDINGS INC (COM SHS), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 2 managers in 2026 Q2

  • 3 Owners
  • Max 1.9%
  • $130M
  • 1 reduce 1 exit 1 small

In 2026 Q2 Jensen Investment Management trimmed Labcorp, and Lee Ainslie sold out.

Who owns this now

Largest portfolio weights among holders, up to 1.9% (Wallace Weitz, Weitz Investment Management). Not free-float ownership.

  1. Wallace Weitz 1.9%
  2. John Rogers Reduce 0.97%
  3. Jensen Investment Management Reduce 0.11%

Who owns LH

Sorted by value, long equity only, as of 2026 Q2.

History
John Rogers, Ariel Investments 0.97%, was 1.1% Small trim −1.4% 349,112 $98M History
Wallace Weitz, Weitz Investment Management 1.9% Hold 99,050 $28M History
Jensen Investment Management 0.11% Reduce −13.1% 16,050 $4.5M History
Lee Ainslie, Maverick Capital exited 2026 Q2 Last 2026 Q1 <0.01% Exit 0.00% 1,596 $426K History

3 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by LH's executives, directors and 10% owners in the last 12 months, from their Form 4s

All LH insider trades
  • None no insider bought on the open market
  • $5.5M sold by 6 insiders outside a trading plan
  • $8.2M sold by 6 insiders under 10b5-1 plans
  1. Kerrii B Anderson Director
    Planned sale
    $954K 3,000 shares at $318.02 31% of stake
    Traded Aug 17 Filed Aug 18
    ↗
  2. Adam H Schechter CEO
    Planned sale
    $1.5M 4,669 shares at $320.37 4.4% of stake
    Traded Aug 11 Filed Aug 12
    ↗
  3. Amy B. Summy EVP, Chief Marketing Officer
    Sale
    $283K 924 shares at $306.74 12% of stake
    Traded Aug 4 Filed Aug 6
    ↗
  4. Peter J Wilkinson SVP, Chief Accounting Officer
    Sale
    $439K 1,420 shares at $309.23 45% of stake
    Traded Aug 3 Filed Aug 5
    ↗
  5. Kathryn W Kyle EVP, Chief Legal Officer
    Planned sale
    $26K 92 shares at $286.19 2.3% of stake
    Traded Jul 2 Filed Jul 6
    ↗
  6. Bryan T Vaughn EVP and President, Diagnostics
    Planned sale
    $67K 234 shares at $286.19 3.4% of stake
    Traded Jul 2 Filed Jul 6
    ↗
  7. Kathryn W Kyle EVP, Chief Legal Officer
    Planned sale
    $201K 762 shares at $263.89 17% of stake
    Traded Jun 8 Filed Jun 10
    ↗
  8. Adam H Schechter CEO
    Planned sale
    $1.5M 5,903 shares at $254.50 5.2% of stake
    Traded May 11 Filed May 13
    ↗
  9. Peter J Wilkinson SVP, Chief Accounting Officer
    Planned sale
    $436K 1,633 shares at $267.05 47% of stake
    Traded Mar 27 Filed Mar 30
    ↗
  10. Jonathan C Meltzer EVP, Operations
    Planned sale
    $224K 839 shares at $267.05 19% of stake
    Traded Mar 27 Filed Mar 30
    ↗
  11. Adam H Schechter CEO
    Sale
    $2.4M 8,705 shares at $279.96 9.7% of stake
    Traded Mar 3 Filed Mar 5
    ↗
  12. Sandra D Van Der Vaart EVP, Corporate Affairs
    Sale
    $156K 548 shares at $284.91 18% of stake
    Traded Feb 27 Filed Mar 3
    ↗
  13. Brian J Caveney EVP, Pres of ED, CMO & CSO
    Sale
    $429K 1,500 shares at $286.31 4.7% of stake
    Traded Feb 24 Filed Feb 26
    ↗
  14. Peter J Wilkinson SVP, Chief Accounting Officer
    Planned sale
    $185K 666 shares at $277.94 26% of stake
    Traded Feb 19 Filed Feb 23
    ↗
  15. Adam H Schechter CEO
    Planned sale
    $1.5M 5,273 shares at $284.38 5.7% of stake
    Traded Feb 11 Filed Feb 13
    ↗

Also filed in the last 12 months, not counted as buying or selling: 60 share withholdings for taxes, 55 option exercises, and 14 stock grants.

Congress

5 members of Congress traded LH in the last three years: 15 buys and 7 sales. 4 members listed it in 2025 annual reports.

All Congress trades
  1. April McClain Delaney D-MD-6Child Sell $100K–$250K Aug 25 filed Sep 9
  2. April McClain Delaney D-MD-6Child Partial sale $1K–$15K Aug 7 filed Sep 9
  3. April McClain Delaney D-MD-6Child Partial sale $1K–$15K Aug 6 filed Sep 9
  4. April McClain Delaney D-MD-6Child Partial sale $1K–$15K Aug 5 filed Sep 9
  5. Alan Armstrong R-OK Buy $1K–$15K Mar 27 filed Jul 21
  6. April McClain Delaney D-MD-6Child Buy $1K–$15K Feb 11 filed Mar 10

SEC filings

Recent issuer filings from EDGAR, 22 shown.

Filed Form Detail Links
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 7.01 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 5.02 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 5.07 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated about 3 hours ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $12.16B $13.01B $13.95B
Gross profit $3.36B $3.62B $4.01B
Gross margin * 27.7% 27.9% 28.8%
Net income $418M $746M $876.5M
Net margin * 3.4% 5.7% 6.3%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $3.77B $4.81B $4.02B
Total non-current assets * $12.96B $13.57B $14.37B
Total assets $16.73B $18.38B $18.39B
Total current liabilities $3.23B $3.33B $2.82B
Total non-current liabilities * $5.61B $6.98B $6.93B
Total equity $7.88B $8.05B $8.62B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $1.33B $1.59B $1.64B
Cash from investing -$1.17B -$1.37B -$1.19B
Cash from financing -$0.059B $0.78B -$1.46B
Net change in cash $106.8M $981.9M -$986.4M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.